Source comparison
Side-by-Side Comparison
Class Non-peptide ghrelin mimetic (GHS) GHRP (Growth Hormone Releasing Peptide) Mechanism Sustained ghrelin/GHS receptor agonism Selective ghrelin/GHS receptor agonism (pulsatile) Evidence Grade B+ Route Oral (capsule/liquid) Subcutaneous injection Typical Dos
This comparison does not assign a generated winner or score.
- Class
- Non-peptide ghrelin mimetic (GHS)
- GHRP (Growth Hormone Releasing Peptide)
- Mechanism
- Sustained ghrelin/GHS receptor agonism
- Selective ghrelin/GHS receptor agonism (pulsatile)
- Evidence Grade
- B+
- Route
- Oral (capsule/liquid)
- Subcutaneous injection
- Typical Dose
- 10 - 25 mg once daily
- 200 - 300 mcg, 2-3x daily
- Half-Life
- ~24 hours
- ~2 hours
- GH Release Pattern
- Sustained elevation (24h)
- Pulsatile (mimics natural rhythm)
- IGF-1 Elevation
- Significant, sustained increase
- Moderate, pulsatile increase
- Appetite Impact
- Significant increase (common)
- Minimal
- Blood Sugar Impact
- May increase fasting glucose
- Cortisol Impact
- Possible mild increase
- Minimal (selective)
- Water Retention
- Common (moderate to significant)
- Mild
- Sleep Quality
- Often improves (deep sleep)
- May improve when dosed before bed
- Convenience
- High (once-daily oral)
- Low (2-3 daily injections)
- FDA Status
- Not approved; investigational
- Not approved; research compound
- Cost (research grade)
- $